Advertisement
Australia markets close in 2 hours 27 minutes
  • ALL ORDS

    8,099.80
    -50.30 (-0.62%)
     
  • ASX 200

    7,830.40
    -50.90 (-0.65%)
     
  • AUD/USD

    0.6664
    -0.0016 (-0.24%)
     
  • OIL

    79.32
    +0.09 (+0.11%)
     
  • GOLD

    2,380.80
    -4.70 (-0.20%)
     
  • Bitcoin AUD

    98,716.33
    -421.14 (-0.42%)
     
  • CMC Crypto 200

    1,377.95
    -16.09 (-1.16%)
     
  • AUD/EUR

    0.6135
    -0.0004 (-0.06%)
     
  • AUD/NZD

    1.0903
    -0.0003 (-0.03%)
     
  • NZX 50

    11,675.37
    -52.69 (-0.45%)
     
  • NASDAQ

    18,557.96
    -38.69 (-0.21%)
     
  • FTSE

    8,438.65
    -7.15 (-0.08%)
     
  • Dow Jones

    39,869.38
    -38.62 (-0.10%)
     
  • DAX

    18,738.81
    -130.55 (-0.69%)
     
  • Hang Seng

    19,409.43
    +32.90 (+0.17%)
     
  • NIKKEI 225

    38,782.08
    -138.18 (-0.36%)
     

Silk Road Medical First Quarter 2024 Earnings: Beats Expectations

Silk Road Medical (NASDAQ:SILK) First Quarter 2024 Results

Key Financial Results

  • Revenue: US$48.5m (up 21% from 1Q 2023).

  • Net loss: US$14.1m (loss narrowed by 14% from 1Q 2023).

  • US$0.36 loss per share (improved from US$0.43 loss in 1Q 2023).

earnings-and-revenue-growth
earnings-and-revenue-growth

All figures shown in the chart above are for the trailing 12 month (TTM) period

Silk Road Medical Revenues and Earnings Beat Expectations

Revenue exceeded analyst estimates by 8.5%. Earnings per share (EPS) also surpassed analyst estimates by 11%.

Looking ahead, revenue is forecast to grow 9.4% p.a. on average during the next 3 years, compared to a 8.1% growth forecast for the Medical Equipment industry in the US.

ADVERTISEMENT

Performance of the American Medical Equipment industry.

The company's shares are up 15% from a week ago.

Risk Analysis

You should always think about risks. Case in point, we've spotted 2 warning signs for Silk Road Medical you should be aware of.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.